Get the Stockscreener App
31.00
5.33%
1.57
Veracyte Inc stock is traded at $31.00, with a volume of 1.05M.
It is up +5.33% in the last 24 hours and up +31.86% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
See More
Previous Close:
$29.43
Open:
$29.76
24h Volume:
1.05M
Relative Volume:
0.76
Market Cap:
$2.44B
Revenue:
$399.58M
Net Income/Loss:
$-54.04M
P/E Ratio:
-41.33
EPS:
-0.75
Net Cash Flow:
$40.13M
1W Performance:
+2.58%
1M Performance:
+31.86%
6M Performance:
-20.88%
1Y Performance:
-0.19%
1-Day Range:
$29.56
$31.30
1-Week Range:
$28.89
$31.30
52-Week Range:
$22.61
$47.32
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
31.00 | 2.37B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte's Turnaround Potential: Navigating Financial Struggles and Strategic Realignments Amidst a Competitive Landscape - AInvest
Veracyte Inc. Recovery Linked to Earnings SurpriseJuly 2025 Retail & Pattern Based Trade Signal System - newsimpact.co.kr
Veracyte Inc. Breaks Losing Streak — Is the Trend Reversing2025 AllTime Highs & Fast Exit and Entry Trade Guides - classian.co.kr
Sentiment Tools Show Shift in Trader Mood on Veracyte Inc.Portfolio Profit Report & Smart Money Movement Tracker - newsimpact.co.kr
Veracyte Inc. Builds Base for Possible ReboundPortfolio Return Report & Risk Adjusted Buy/Sell Alerts - thegnnews.com
Trapped Investors in Veracyte Inc. Await Breakout SignalWeekly Loss Report & Short-Term Trading Alerts - sundaytimes.kr
Volatility clustering patterns for Veracyte Inc.Quarterly Profit Review & Long-Term Capital Growth Strategies - Newser
Veracyte Inc.’s volatility index tracking explainedMarket Rally & AI Enhanced Execution Alerts - Newser
Is a relief rally coming for Veracyte Inc. holdersJuly 2025 Momentum & Technical Pattern Based Signals - Newser
Forecasting Veracyte Inc. price range with options data2025 EndofYear Setup & Free Expert Verified Stock Movement Alerts - Newser
Real time alert setup for Veracyte Inc. performanceInsider Buying & Stock Portfolio Risk Control - Newser
Is now a turning point for Veracyte Inc.July 2025 Sentiment & Stock Market Timing Techniques - Newser
Why Veracyte Inc. stock attracts strong analyst attentionWeekly Loss Report & Daily Momentum Trading Reports - Newser
Here's Why Veracyte (VCYT) is a Strong Growth Stock - Yahoo Finance
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality - Yahoo Finance
Veracyte Inc. Inches Above Key Support — Safe to HoldJuly 2025 Institutional & Free Real-Time Volume Trigger Notifications - thegnnews.com
PNC Financial Services Group Inc. Cuts Holdings in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
How Resilient Is Veracyte Inc. Stock During Economic Downturns2025 Technical Overview & Free Fast Entry Momentum Trade Alerts - Newser
Veracyte, Inc. (NASDAQ:VCYT) Shares Purchased by Blair William & Co. IL - Defense World
VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up - Yahoo Finance
Veracyte, Inc. (NASDAQ:VCYT) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Is Veracyte Inc. a Top Dividend Stock to Watch in 2025Price Movement and Market Sentiment Analysis - Newser
Candlestick Signal Suggests Reversal in Veracyte Inc.Chart-Based Trade Entries Gain Analyst Support - metal.it
Veracyte stock price target lowered to $28 from $29 at Morgan Stanley By Investing.com - Investing.com South Africa
Veracyte stock price target lowered to $28 from $29 at Morgan Stanley - Investing.com Australia
Cautious Outlook on Veracyte: Sell Rating Amid Market Uncertainties and Valuation Concerns - TipRanks
Veracyte price target lowered to $28 from $29 at Morgan Stanley - TipRanks
A Quick Look at Today's Ratings for Veracyte(VCYT.US), With a Forecast Between $41 to $45 - 富途牛牛
Veracyte, Inc. (NASDAQ:VCYT) Q2 2025 Earnings Call Transcript - Insider Monkey
Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight - GuruFocus
Veracyte Inc’s Earnings Call Highlights Robust Growth and Strategic Milestones - TipRanks
Veracyte Receives Buy Rating and $37 Price Target from Guggenheim Analyst - AInvest
Veracyte’s Revenue Growth Outpaces Forecasts And Lifts Guidance - Finimize
Veracyte’s Strong Financial Performance and Promising Growth Prospects Justify Buy Rating - TipRanks
Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care - AInvest
Veracyte (VCYT) Q2 Revenue Jumps 14% - AOL.com
Veracyte stock rating reiterated at Outperform by William Blair - Investing.com India
Earnings call transcript: Veracyte’s Q2 2025 earnings beat expectations, stock falls - Investing.com Canada
Earnings call transcript: Veracyte’s Q2 2025 earnings beat expectations, stock falls By Investing.com - Investing.com South Africa
Transcript : Veracyte, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Veracyte: Q2 Earnings Snapshot - Greenwich Time
Veracyte's 2025 Q2 Financial Performance and Strategic Momentum: A Deep Dive into Diagnostic Innovation and Oncology Expansion - AInvest
Veracyte Announces Second Quarter 2025 Financial Results - BioSpace
Veracyte's 2025 Earnings Call: A Catalyst-Driven Path to Sustained Double-Digit Growth and 25%+ Adjusted EBITDA Margins - AInvest
Veracyte Reports Strong Q2 2025 Revenue Growth - TipRanks
Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
Veracyte Q2 2025 slides: Decipher drives 14% revenue growth, EBITDA margins expand - Investing.com Nigeria
Veracyte Q2 revenue rises 14%, beats expectations - MarketScreener
Veracyte Inc (VCYT) Q2 2025 Earnings: Revenue Surpasses Estimates at $130.2M, Reports GAAP Net Loss - GuruFocus
Veracyte shares surge as Q2 profits quadruple expectations By Investing.com - Investing.com Nigeria
Veracyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Veracyte Inc Stock (VCYT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bhanji Muna | Director |
Jun 13 '25 |
Sale |
26.67 |
4,589 |
122,367 |
29,989 |
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):